Pharma & Biotech — 2026年10月26日 週次レポート
Pharma & Biotechのニュース＆アップデート — すべての記述に一次ソースのリンク付き。
重要な発見
エグゼクティブサマリー（4件）
- •The ESMO 2026 congress served as the week's scientific centrepiece, delivering the most consequential oncology data package of the year: Merck and Moderna's Phase 3 mRNA cancer vaccine confirmation, J&J's RIPTAC prostate cancer breakthrough, and AstraZeneca's lung cancer combination data collectively signal that multiple next-generation oncology platforms are simultaneously crossing from clinical validation into commercial reality — a convergence that will reshape competitive dynamics in oncolog…
- •The US-China biotech relationship entered a structurally new phase this week, with the US Treasury's COINS proposal and China's foreign acquisition restrictions creating bidirectional decoupling pressure. The paradox is acute: even as these restrictions were announced, Roche and Gilead completed deals worth over $16 billion combined with Chinese companies, illustrating that the commercial imperative to access China's drug discovery engine is currently stronger than the geopolitical pressure to d…
- •The MHRA continued its role as the world's most active drug approval authority this week, adding plozasiran, a new oral psoriasis treatment, and deuruxolitinib to its approval list while confirming indefinite CE mark recognition — actions that collectively reinforce the UK's post-Brexit positioning as a regulatory jurisdiction that combines speed, breadth, and continuity for market access.
- •The Bristol Myers Squibb CAR-T patient death in an MS trial introduces a material safety question for the autoimmune CAR-T field at a critical juncture, potentially shifting competitive advantage toward bispecific antibody approaches like J&J's TALVEY that offer comparable efficacy with a more established safety profile — a dynamic that could reshape investment and development priorities across the autoimmune pipeline.
今回の要点（15件）
- 1.Merck and Moderna presented Phase 3 INTerpath-001 results for intismeran autogene plus KEYTRUDA at the ESMO 2026 Presidential Symposium, with STAT News confirming on 2026-10-23 that detailed data confirmed the cancer vaccine met key endpoints in melanoma [2].
- 2.The Trump administration proposed on 2026-10-23 a COINS Act rule that would add biotechnology to national security outbound investment restrictions, prohibiting U.S. companies from entering financial transactions with Chinese biotech companies while still allowing drug rights purchases [14].
- 3.China moved to restrict foreign biotech acquisitions, reported by STAT News on 2026-10-19, creating a bidirectional tightening of US-China biotech relationships [2a].
- 4.Roche struck a deal with China's Hansoh Pharmaceutical Group worth up to $15 billion with $400 million upfront for a portfolio of antibody-drug conjugates, reported by STAT News on 2026-10-20 [15].
- 5.Gilead struck a $1.3 billion upfront China deal for an oral IL-23 drug, reported by Endpoints News on 2026-10-23 [7].
- 6.A patient died in a Bristol Myers Squibb autoimmune CAR-T trial, reported by STAT News on 2026-10-23, introducing a safety overhang for the autoimmune CAR-T field [2].
- 7.J&J reported on 2026-10-25 that its first-in-class RIPTAC molecule JNJ-6143 achieved a 75% tumor response rate in advanced prostate cancer in Phase 1, with 77% of patients achieving a confirmed PSA reduction of at least 50% [10].
- 8.J&J announced on 2026-10-24 that ERLEADA treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer [10].
- 9.The MHRA authorised plozasiran (Redemplo) for familial chylomicronaemia syndrome on 2026-10-19, approved a new oral plaque psoriasis treatment and deuruxolitinib (Leqselvi) for alopecia areata on 2026-10-23, and confirmed indefinite CE mark recognition on 2026-10-21 [13].
- 10.Merck received European Commission approval on 2026-10-21 for KEYTRUDA plus Padcev as perioperative treatment for resectable muscle-invasive bladder cancer [3].
- 11.GSK received FDA approval for a hepatitis B drug offering a functional cure, reported by Endpoints News on 2026-10-21 [7].
- 12.STAT News reported on 2026-10-22 that telehealth companies are already marketing off-label GLP-1 prescriptions for addiction treatment ahead of FDA approval, with some offering compounded versions [2b].
- 13.AI drug firm Pathos raised $237 million at a $3 billion valuation, reported by STAT News on 2026-10-23 [2].
- 14.Japan's PMDA published the basic policy for the 20th revision of the Japanese Pharmacopoeia and new Early Consideration guidance on companion diagnostics on 2026-10-19 [5].
- 15.The EMA and AMA issued joint guidance on Ebola vaccine development on 2026-10-23, defining clinical trial requirements for rapid development of Bundibugyo virus vaccines [4].
市場動向
mRNA Cancer Vaccine Achieves Phase 3 Landmark at ESMO, Expanding Platform Ambitions
Merck and Moderna presented Phase 3 INTerpath-001 trial results for intismeran autogene plus KEYTRUDA at the ESMO 2026 Presidential Symposium, with STAT News reporting on 2026-10-23 that detailed data confirmed the cancer vaccine met key endpoints in melanoma [2]. Endpoints News described the data as 'a triumph of science' on 2026-10-25 [7]. STAT News also reported on 2026-10-25 that after this first success, the race is now on to expand the impact of the approach [2]. This transition from initi…
US-China Biotech Decoupling Accelerates as Treasury Proposes COINS Investment Restrictions
The Trump administration proposed a rule on 2026-10-23 that would severely restrict future U.S. investment in the Chinese biotech sector under the Comprehensive Outbound Investment National Security Act, adding biotechnology to the list of industries subject to COINS restrictions alongside semiconductors, AI, and quantum technology [14]. According to STAT News, the proposal would prohibit U.S. companies from entering financial transactions with Chinese biotech companies or Chinese manufacturers …
Western Pharma Doubles Down on China Drug Sourcing Despite Geopolitical Headwinds
Even as investment restrictions loom, major Western companies continued to pursue Chinese drug assets this week. STAT News reported on 2026-10-20 that China's Hansoh Pharmaceutical Group struck a massive deal with Roche to develop a portfolio of antibody-drug conjugates, with Roche paying $400 million upfront in a deal worth up to $15 billion [15]. Endpoints News reported on 2026-10-23 that Gilead struck a $1.3 billion upfront China deal for an oral IL-23 drug [7]. The COINS proposal explicitly …
GLP-1 Expansion Into Addiction Treatment Outpaces Regulatory Approval
STAT News reported on 2026-10-22 that telehealth companies including Quel, Livelyhood, and Choose Your Horizon are already marketing off-label prescriptions of GLP-1 drugs — including compounded versions — to people struggling with substance use disorders, ahead of any FDA approval for these indications [2b]. Endpoints News reported on 2026-10-22 that big trials are pushing beyond obesity to test whether GLP-1s can quell alcohol and drug cravings [7]. The gap between commercial deployment and re…
AI Drug Discovery Investment Surges as Platforms Seek Clinical Validation
STAT News reported on 2026-10-23 that AI drug firm Pathos raised $237 million, pushing its valuation to $3 billion [2]. STAT News also reported on 2026-10-19 that Isomorphic Labs — DeepMind's drug discovery spinout — is being scrutinised for whether it has what it takes to revolutionise drugmaking [2]. Nature Biotechnology highlighted Bioptimus as its editor's pick on 2026-10-19, describing the company as developing multimodal and multiscale AI pathology models for biomarker and drug treatment p…
競合動向
Merck and Moderna Validate mRNA Cancer Vaccine at Phase 3, Setting New Oncology Benchmark
Merck announced on 2026-10-22 that it and Moderna would present Phase 3 INTerpath-001 results for intismeran autogene plus KEYTRUDA at the ESMO 2026 Presidential Symposium [3] (company announcement — may reflect promotional framing). STAT News confirmed on 2026-10-23 that detailed data confirmed the cancer vaccine met key endpoints in the melanoma trial [2]. Separately, Merck received European Commission approval on 2026-10-21 for KEYTRUDA plus Padcev as perioperative treatment for adults with r…
Johnson & Johnson Advances Solid Tumor and Prostate Cancer Pipeline at ESMO
J&J announced on 2026-10-23 new data at ESMO 2026 including the first readout from its RIPTAC platform showing promising anti-tumor activity with JNJ-6143 in prostate cancer, and new first-line head and neck cancer data for RYBREVANT FASPRO [10] (company announcement — may reflect promotional framing). On 2026-10-25, J&J reported that JNJ-6143 achieved a 75% tumor response rate in advanced prostate cancer in Phase 1, with 77% of patients achieving a confirmed PSA reduction of at least 50% [10] (…
Roche Pursues Dual China Strategy: Licensing Deals While Facing Pipeline Cuts
STAT News reported on 2026-10-20 that Hansoh Pharmaceutical Group struck a deal with Roche worth up to $15 billion with $400 million upfront for a portfolio of antibody-drug conjugates [15]. Endpoints News reported on 2026-10-22 that Roche talked up its Phase 3 success rate while unveiling pipeline cuts [7]. Endpoints News also reported on 2026-10-23 that Roche tapped Zymeworks in a deal worth up to $813 million for a preclinical T cell engager [7]. Roche's simultaneous pipeline rationalisation …
GSK Secures FDA Approval for Hepatitis B Functional Cure Drug
Endpoints News reported on 2026-10-21 that GSK received FDA approval for a hepatitis B drug that offers a functional cure [7]. STAT News reported on 2026-10-21 that GSK picked up the hepatitis B drug approval [2c]. This approval represents a significant competitive advance for GSK in infectious disease, as a functional cure for hepatitis B has been a long-sought goal in the field and positions GSK ahead of competitors still in development for this indication.
Bristol Myers Squibb Faces CAR-T Safety Scrutiny After Patient Death in MS Trial
STAT News reported on 2026-10-23 that a patient died in a Bristol Myers Squibb autoimmune CAR-T trial [2]. Endpoints News reported on 2026-10-23 that Bristol Myers revealed the death in an MS CAR-T trial and provided an answer for a safety signal in a lupus trial [7]. Endpoints News also published a Q&A with Bristol Myers' Lynelle Hoch on autoimmune CAR-T safety challenges on 2026-10-24 [7]. The patient death introduces a significant safety overhang for BMS's autoimmune CAR-T program at a time w…
制度・規制動向
US Treasury COINS Proposal Adds Biotech to National Security Investment Restrictions
The Trump administration proposed on 2026-10-23 a rule under the Comprehensive Outbound Investment National Security Act that would add biotechnology to the list of industries subject to outbound investment restrictions, alongside semiconductors, AI, and quantum technology [14]. According to STAT News, the proposal would prohibit U.S. companies from entering financial transactions with Chinese biotech companies or Chinese manufacturers of biotechnology-related equipment and tools, though it woul…
MHRA Delivers Multiple New Drug Approvals and Confirms Indefinite CE Mark Recognition
The MHRA authorised plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome on 2026-10-19 [13]. On 2026-10-21, the UK government confirmed indefinite recognition of CE marked medical devices, ensuring continued patient access to devices approved for the EU market [13]. On 2026-10-23, the MHRA approved a new oral treatment for moderate to severe plaque psoriasis and approved deuruxolitinib (Leqselvi) for severe alopecia areata in adults [13]. The combination of new drug approvals…
EMA Issues Joint Ebola Vaccine Guidance and Maintains High Approval Throughput
The EMA and AMA issued joint guidance on Ebola vaccine development on 2026-10-23, defining clinical trial requirements for rapid development of Bundibugyo virus vaccines [4]. This follows the EMA's CHMP October meeting that recommended six new medicines and five indication extensions, including the oral GLP-1 tablet and Rasonque for pancreatic cancer [4]. The joint Ebola guidance reflects the EMA's pandemic preparedness mandate being operationalised at the vaccine development level, consistent w…
PMDA Advances 20th Japanese Pharmacopoeia Revision and Companion Diagnostic Standards
Japan's PMDA published the basic policy for the 20th revision of the Japanese Pharmacopoeia on 2026-10-19 [5]. On the same date, PMDA published Early Consideration guidance on companion diagnostics developed in parallel with anticancer agents, and on extracellular vesicle (EV) product quality requirements at the time of initial clinical trial notification [5]. PMDA also published an ICMRA statement on animal testing for human medicines on 2026-10-23 [5]. These updates collectively signal Japan's…
FDA Publishes New Guidance on Clinical Trial Data Submission and Drug-Related Software
The FDA published guidance on submitting clinical trial data to evaluate the ability to operate a motor vehicle on 2026-10-20, providing technical specifications for driving studies to support marketing applications [12]. The FDA also published guidance on regulatory considerations for prescription drug use-related software on 2026-10-20 [12]. These publications reflect the FDA's ongoing effort to provide technical clarity for novel data types and digital health applications in drug development,…
ソース活動
先週からの変化
US Treasury Proposes COINS Biotech Investment Restrictions on China
The Trump administration proposed on 2026-10-23 a rule under the COINS Act that would severely restrict future U.S. investment in the Chinese biotech sector, adding biotechnology to national security investment restrictions alongside semiconductors and AI, while still allowing drug rights purchases [14]. This is the most consequential US regulatory action affecting pharma-China relationships this period, escalating from the prior period's Chinese government export ban pursuit to a formal US Trea…
Merck-Moderna mRNA Cancer Vaccine Phase 3 Data Confirmed at ESMO
Merck and Moderna presented Phase 3 INTerpath-001 trial results at the ESMO 2026 Presidential Symposium, with STAT News confirming on 2026-10-23 that detailed data confirmed the cancer vaccine met key endpoints in melanoma [2]. Merck's press release on 2026-10-22 announced the ESMO presentation [3]. This updates the prior period's item on Merck and Moderna having 'a lot of exploring to do' — the Phase 3 data readout has now occurred and confirmed efficacy, moving the program from planning to val…
Bristol Myers Squibb Patient Death in Autoimmune CAR-T Trial
STAT News reported on 2026-10-23 that a patient died in a Bristol Myers Squibb autoimmune CAR-T trial [2]. Endpoints News corroborated the report and noted BMS also addressed a safety signal in a lupus trial [7]. This is a new safety development with potential implications for the broader autoimmune CAR-T field and BMS's competitive positioning against bispecific antibody approaches.
MHRA Approves Multiple New Drugs and Confirms Indefinite CE Mark Recognition
The MHRA authorised plozasiran (Redemplo) for familial chylomicronaemia syndrome on 2026-10-19, approved a new oral plaque psoriasis treatment and deuruxolitinib (Leqselvi) for alopecia areata on 2026-10-23, and confirmed indefinite recognition of CE marked medical devices on 2026-10-21 [13]. These actions extend the MHRA's active approval cadence established in the prior period and add post-Brexit regulatory continuity clarity for device manufacturers.
China Biotech Decoupling Intensifies: Bidirectional Restrictions Emerge
The prior period's item on China's export ban pursuit has escalated into a bidirectional decoupling: China moved to restrict foreign biotech acquisitions (STAT News, 2026-10-19) [2a] while the US Treasury proposed COINS restrictions on outbound biotech investment (2026-10-23) [14]. Despite this, Roche and Gilead both completed major China licensing deals this week, illustrating the tension between geopolitical restrictions and commercial drug sourcing imperatives.
ウォッチリスト — 今後の締切
EMA clinical trial applications advice pilot becomes permanent — technical and regulatory support for preparing clinical trial applications continues from January 2027
ソース: EMA NewsRoivant plans to seek expanded FDA approval for Lisraya in non-infectious uveitis in the first half of 2027
ソース: STAT News示唆・見るべき論点（8件）
- 1.The Merck-Moderna Phase 3 cancer vaccine confirmation at ESMO transforms the competitive calculus for personalised oncology: every major oncology company must now assess whether to develop its own mRNA neoantigen vaccine program or risk ceding the adjuvant melanoma market — and potentially other solid tumor indications — to the Merck-Moderna partnership [2].
- 2.The COINS proposal's carve-out allowing drug rights purchases while prohibiting equity investment creates a structural incentive for Western pharma to shift from equity partnerships with Chinese biotechs to pure licensing arrangements — a model that benefits Chinese companies (who retain equity upside) while limiting US investors' ability to participate in China's biotech growth [14].
- 3.The BMS CAR-T patient death in an MS trial [2] arrives at a moment when autoimmune CAR-T is being positioned as a potential cure for conditions like lupus and MS. A single safety event in a small trial can disproportionately affect regulatory and investor confidence in an entire modality — companies with autoimmune CAR-T programs should proactively engage with regulators on safety monitoring protocols.
- 4.J&J's 75% tumor response rate for JNJ-6143 in prostate cancer [10] represents the first clinical validation of the RIPTAC platform, which uses a targeted dual-protein lock mechanism distinct from existing small molecule approaches. If confirmed in larger trials, this could establish a new class of targeted protein degraders with implications beyond prostate cancer.
- 5.The MHRA's indefinite CE mark recognition [13] removes a major post-Brexit uncertainty for medical device manufacturers, effectively creating a dual-pathway market where EU-approved devices automatically qualify for UK use. This reduces the regulatory burden for device companies and may accelerate UK market entry relative to the pre-Brexit era.
- 6.The proliferation of off-label GLP-1 prescriptions for addiction via telehealth platforms [2b] is creating a regulatory arbitrage situation that the FDA will eventually need to address. Companies with GLP-1 programs in addiction indications should accelerate their regulatory submissions to establish approved labelling before the off-label market becomes entrenched and harder to displace.
- 7.Roche's simultaneous pipeline cuts and $15 billion China licensing deal [15] illustrates a broader industry pattern: internal R&D productivity is being supplemented — and in some cases replaced — by external sourcing from China's lower-cost, faster-moving drug discovery ecosystem. The COINS proposal, if finalised, would force companies to choose between this efficiency and US regulatory compliance.
- 8.The EMA-AMA joint Ebola vaccine guidance [4] and IFPMA's pandemic preparedness advocacy [1] signal that the regulatory and industry infrastructure for rapid vaccine development is being institutionalised in response to the Political Declaration on PPPR — creating a more predictable development pathway for future outbreak vaccines that could reduce the timeline from pathogen identification to regulatory submission.
信頼度サマリー
今週引用したソース 15 件あなたが選んだ 15 件の監視URLから検出（1つのURLから複数記事が出ることがあります）。
各ソースは信頼度レベルに応じて重み付けされています。単独ソースの主張は AI 合成時に未検証としてフラグ付けされます。
参照ソース一覧
IFPMA published a statement on CBD COP17 digital sequence information (2026-10-19) and an expert insight on re-centering ethics as pharma's competitive advantage on Global Ethics Day (2026-10-21).
STAT News reporting covering Merck-Moderna Phase 3 cancer vaccine data at ESMO (2026-10-23), Treasury COINS biotech investment restrictions proposal (2026-10-23), China biotech acquisition restrictions (2026-10-19), Roche-Hansoh $15B ADC deal (2026-10-20), BMS CAR-T patient death (2026-10-23), GLP-1 off-label addiction telehealth (2026-10-22), Pathos $237M AI drug raise (2026-10-23), and Novartis MS treatment pivotal trial results (2026-10-23).
Merck press releases covering European Commission approval of KEYTRUDA plus Padcev for resectable MIBC (2026-10-21) and announcement of Phase 3 INTerpath-001 cancer vaccine results presentation at ESMO 2026 Presidential Symposium (2026-10-22).
EMA news covering joint AMA-EMA guidance on Ebola vaccine development defining clinical trial requirements for Bundibugyo virus vaccines (2026-10-23), and the CHMP October 12-15 meeting highlights recommending six new medicines.
PMDA updates covering publication of basic policy for 20th revision of Japanese Pharmacopoeia (2026-10-19), Early Consideration guidance on companion diagnostics and extracellular vesicle products (2026-10-19), ICMRA statement on animal testing for human medicines (2026-10-23), and safety notices including avacopan product precautions (2026-10-21).
EFPIA updates showing stable content with ongoing advocacy on single regulatory pathway for AI-enabled medical technologies (2026-10-15) and Urban Wastewater Treatment Directive pause (2026-10-12), with new event listings for November 2026 QPPV Forum and life sciences competitiveness agenda.
Endpoints News reporting on Merck KGaA acquisition of Silence Therapeutics for $1.3B (2026-10-19), Roche $400M upfront $15B Hansoh ADC deal (2026-10-19), GSK FDA hepatitis B functional cure approval (2026-10-21), Treasury COINS biotech restrictions (2026-10-22-23), BMS CAR-T MS patient death (2026-10-23), Roche Zymeworks T cell engager deal up to $813M (2026-10-23), Gilead $1.3B China IL-23 deal (2026-10-23), and Amgen Imdelltra small cell lung cancer data (2026-10-24).
Pfizer press release page showing no new releases this week beyond previously reported items; site experienced security verification interruptions on 2026-10-21 and 2026-10-24.
Nature Biotechnology publishing new research articles on transcriptome-wide single-cell RNA recording using Recordanelles (2026-10-21), engineered human Argonaute 2 for RNA base editing (2026-10-20), and editor's pick on Bioptimus AI pathology models (2026-10-19).
J&J press releases covering TREMFYA 48-week fistula remission data in Crohn's disease (2026-10-19), rheumatology data at ACR Convergence 2026 including nipocalimab in Sjögren's and SLE (2026-10-22), ESMO solid tumor data including JNJ-6143 RIPTAC platform and RYBREVANT FASPRO (2026-10-23), ERLEADA 62% recurrence/death risk reduction in prostate cancer (2026-10-24), and 75% tumor response rate for JNJ-6143 in Phase 1 (2026-10-25).
DIA Global updated content on ASEAN joint assessment procedures for marketing applications and challenges in evaluating multicancer early detection tests, alongside the ongoing DIA-MHRA Global Summit announcement.
FDA published guidance on submitting clinical trial data to evaluate ability to operate a motor vehicle (2026-10-20) and regulatory considerations for prescription drug use-related software (2026-10-20), alongside safety reporting requirements for INDs and BA/BE studies (2026-10-19).
MHRA press releases covering authorisation of plozasiran (Redemplo) for familial chylomicronaemia syndrome (2026-10-19), MHRA AI and MedTech agenda at AdvaMed (2026-10-19), indefinite recognition of CE marked medical devices (2026-10-21), approval of new oral plaque psoriasis treatment and deuruxolitinib (Leqselvi) for alopecia areata (2026-10-23).
STAT News detailed reporting on the Treasury Department's proposed COINS Act rule to restrict U.S. investment in Chinese biotech sector, describing the proposal as more aggressive than anticipated but subject to change.
STAT News reporting on Roche's deal with Hansoh Pharmaceutical Group for a portfolio of antibody-drug conjugates, with $400 million upfront and up to $15 billion total value.
Pharma & Biotechを毎週、自動で監視
このレポートは一次ソースのみから生成されています。テーマとソースを選べば、引用付きレポートが毎週届きます。7日間無料トライアル・$33/月から。
無料トライアルを始める